Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideShannon R. McCurdy, Yvette L. Kasamon, Gabrielle T. Prince et al.|Blood|2015Cited by 299
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R. McCurdy, Leo Luznik, Yvette L. Kasamon et al.|Haematologica|2016Cited by 187
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamideAmy E. DeZern, Robert A. Brodsky, Marianna Zahurak et al.|Blood Advances|2020Cited by 149
Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic AnemiaAmy E. DeZern, Robert A. Brodsky, Marianna Zahurak et al.|Biology of Blood and Marrow Transplantation|2016Cited by 132
Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant DisordersOrly R. Klein, Heather J. Symons, Allen Chen et al.|Biology of Blood and Marrow Transplantation|2016Cited by 76